Rapid Health Technology Assessment of Caspofungin in the Prevention and Treatment of Invasive Fungal Diseases

doi:10.14009/j.issn.1672-2124.2021.04.019

您当前的位置：

首页 >

文章列表页 >

Rapid Health Technology Assessment of Caspofungin in the Prevention and Treatment of Invasive Fungal Diseases

更新时间：2022-10-08

- Rapid Health Technology Assessment of Caspofungin in the Prevention and Treatment of Invasive Fungal Diseases
- Vol. 21, Issue 4, Pages: 464-468(2021)
- 作者机构：
  
  北京医院药学部国家老年医学中心,中国医学科学院老年医学研究所,北京市药物临床风险与个体化应用评价重点实验室（北京医院）
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2021.04.019
  CLC： R519
- Published：2021，
扫描看全文
[1]李超,张田,李婷,裴艺芳,谭玲.卡泊芬净预防和治疗侵袭性真菌病的快速卫生技术评估[J].中国医院用药评价与分析,2021,21(04):464-468.

Rapid Health Technology Assessment of Caspofungin in the Prevention and Treatment of Invasive Fungal Diseases. [J]. 21(4):464-468(2021)
[1]李超,张田,李婷,裴艺芳,谭玲.卡泊芬净预防和治疗侵袭性真菌病的快速卫生技术评估[J].中国医院用药评价与分析,2021,21(04):464-468. DOI： 10.14009/j.issn.1672-2124.2021.04.019.

Rapid Health Technology Assessment of Caspofungin in the Prevention and Treatment of Invasive Fungal Diseases. [J]. 21(4):464-468(2021) DOI： 10.14009/j.issn.1672-2124.2021.04.019.

摘要

目的:通过对卡泊芬净预防和治疗侵袭性真菌病的安全性、有效性及经济性进行快速卫生技术评估（health technology assessment

HTA）

为临床合理用药及各层面的决策提供循证依据。方法:系统检索Pub Med、EMBase、the Cochrane Library、中国知网、万方数据库、维普数据库和国内外HTA机构官方网站

纳入卡泊芬净对比其他阳性药或联合用药预防或治疗侵袭性真菌感染的HTA报告、系统评价/荟萃分析（Meta分析）和药物经济学研究

并对纳入文献进行统计分析。结果与结论:最终纳入14篇Meta分析、22篇药物经济学研究。结果显示

卡泊芬净在治疗或预防侵袭性真菌感染过程中

具有良好的安全性

其有效性不劣于其他抗真菌药。经济性方面

在大多数发达国家（如美国、英国、法国、德国、意大利和澳大利亚等）

卡泊芬净均具有成本-效果优势。在我国开展的药物经济学研究中

仅在粒细胞缺乏伴发热患者的初始经验性抗真菌治疗时

卡泊芬净比伏立康唑更经济;在预防和治疗侵袭性真菌感染时

氟康唑及米卡芬净均比卡泊芬净更经济。当然

对于卡泊芬净在我国的经济性评价还需要深入开展更多大规模的研究

以支持决策。

Abstract

OBJECTIVE: To perform health technology assessment（ HTA） based on the safety

effectiveness and economy of caspofungin in the prevention and treatment of invasive fungal diseases

so as to provide evidence-based basis for clinical rational drug use and decision-making at all levels. METHODS: PubMed

EMBase

the Cochrane Library

CNKI

Wanfang database

VIP database and official website of domestic and foreign HTA institutions were retrieved to collect HTA report

systematic review/Meta-analysis and pharmacoeconomic studies on the prevention or treatment of invasive fungal infection with capofungine compared with other positive drugs or combination drugs.Statistical analysis was performed on the included literature. RESULTS & CONCLUSIONS: Fourteen Meta analyses and22 pharmacoeconomic studies were included. In the treatment or prevention of invasive fungal infection

caspofunnet had higher safety and better effectiveness than other antifungal agents. In most developed countries（ such as the United States

the United Kingdom

France

Germany

Italy

Australia）

caspofunnet had cost-effectiveness advantage. In the pharmacoeconomics studies carried out in China

caspofungin is more economical than voriconazole in the initial empirical antifungal treatment of patients with agranulocytosis and fever. In the prevention and treatment of invasive fungal infection

fluconazole and micafungin are more economical than caspofungin. For the economic evaluation of caspofungin in China

more in-depth and large-scale studies are needed to support the decision-making.

关键词

卡泊芬净侵袭性真菌病有效性安全性经济性

Keywords

CaspofunginInvasive fungal diseasesEffectivenessSafetyEconomics

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Evidence-Based Evaluation on Huoxiang Zhengqi Oral Preparation in the Treatment of Gastrointestinal Dysfunction

Efficacy and Economic Evaluation of Atorvastatin Calcium Tablets Generics and Original Drugs in the Treatment of Hyperlipidemia

Rapid Health Technology Assessment of Ozagrelay Sodium Injection for Acute Cerebral Infarction

Systematic Review of Efficacy and Safety of Sacubitril Valsartan in the Treatment of Hypertension

Efficacy and Safety of Compound Lactobacillus Acidophilus Combined with Different Antispasmodic Agents in the Treatment of Diarrhea Irritable Bowel Syndrome: A Systematic Review

Related Author

CAO Miaomiao

MEN Peng

WEN Jian

LIU Li

YANG Yiheng

ZHAO Rongsheng

XIE Qian

LI Na

Related Institution

Peking University Health Science Center’s Institute for Drug Evaluation

Beijing Center for Pharmaceutical Quality Control and Improvement

Dept.of Pharmacy,Peking University Third Hospital

Dept.of Endocrinology,Qianjiang Central Hospital of Chongqing

Dept.of Pharmacy,Qianjiang Central Hospital of Chongqing

⁰